Our commitment to corporate governance underpins the trust that our investors, employees and institutions have in us. We maintain our efforts to build confidence as we continue to grow.

Management Board

Valneva’s Management Board is a highly dedicated international team, with diverse backgrounds, experience, expertise and skills.

Thomas Lingelbach Chief Executive Officer, Chair of the Management Board

Thomas Lingelbach was CEO of Intercell and founding President and CEO of Valneva.

He is an established vaccine industry leader with breadth of experience including senior and executive management roles with Intercell, Novartis and Chiron.

During his more than 30 years in vaccines, he held a variety of positions from product development to commercialization with a strong emphasis on technical development and operations.

In different capacities, he contributed to the successful development and licensure of more than ten vaccines.

Thomas holds an engineering degree, specialized in bioprocess engineering and complemented his education with a business administration program.

He is a German national.

Peter Bühler Chief Financial Officer

Peter Bühler joined Valneva in January 2022.

He has over 20 years of experience in the strategic and financial leadership of life science and technology companies.

Prior to Valneva, he served as CFO of Nasdaq-listed Swiss diagnostics company Quotient. He also served as Group CFO of Zaluvida AG and as Group CFO of Stallergenes Greer Plc. In this capacity, he led a complex merger project between a French and a U.S. company.

Prior to this, Peter had senior roles with Eli Lilly, Merck Serono and Logitech.

He is a Swiss Certified Accountant and holds an MBA.

Peter is a Swiss national.

Franck Grimaud Chief Business Officer, “Directeur Général”*

Franck Grimaud was co-founder, President and CEO of Vivalis and co-led its merger with Intercell to create Valneva.

He has a long-standing and proven track record in corporate and business development as well as strategic management with more than 20 years in the biotech industry.

Prior to creating and successfully building Vivalis as a French public biotech company he was responsible for the creation of the Asian subsidiaries of Groupe Grimaud, a leader in animal genetic selection and currently Valneva´s largest shareholder.

Franck holds an MBA.

He is a French national.

*) Managing Director under the French commercial code i.e. having statutory authority to represent the company legally, in addition to the CEO

Frederic Jacotot General Counsel and Corporate Secretary

Frederic Jacotot joined Valneva as VP Legal and IP and General Counsel shortly after the creation of the Company, and joined the Management Board in April 2017.

He is an established legal expert with a broad business experience in the pharmaceutical industry.

During his more than 30 years in the industry he held a variety of positions with increasing international responsibilities and, prior to Valneva, served as Division Counsel at Abbott.

Frederic holds a Master’s degree in business law.

He is a French national.

Juan Carlos Jaramillo, MD Chief Medical Officer

Juan Carlos Jaramillo, MD joined Valneva in October 2020.

He is an experienced Research and Development leader with a broad expertise in medical affairs, clinical development, as well as market access and pricing.

During his more than 20 years in the pharmaceutical industry and prior to joining Valneva, he held senior management roles with Daiichi Sankyo, Grünenthal and GSK.

Due to his broad exposure to diverse pharma and vaccine roles, he has an in-depth business understanding and a strong track record across a wide range of prophylactic and therapeutic areas and geographies.

Juan Carlos is a Medical Doctor.

He has dual citizenship (Colombian and U.S.).

Dipal Patel Chief Commercial Officer

Dipal Patel joined Valneva in November 2022.

She is an established commercial leader, who joined Valneva from GSK where she held, for more than 20 years, roles of increasing responsibilities across multiple countries including U.S., Australia, Belgium, Singapore, Thailand, and the European and emerging markets.

Her considerable experience covers commercial strategy, execution, market access and lifecycle management.

Over the last few years, Dipal has been Global Commercial Head of GSK’s shingles vaccine (Shingrix®), leading a global cross-functional team establishing it as a global brand with significant worldwide expansion.

Dipal holds an MBA.

She is an Australian national.

Supervisory Board

As part of Valneva’s corporate governance system, the Supervisory Board participates actively in reviewing the Company’s strategic options and setting direction together with the Management Board.

Frédéric Grimaud (FR)

Chairman of Valneva’s Supervisory Board, Representative of the Company's largest shareholder, President and CEO of Groupe Grimaud.

James Sulat (U.S.)

Member of the Supervisory Board & Chair - Audit Committee, Former CFO for Chiron and CEO of Maxygen.

Anne-Marie Graffin (FR)

Member of the Supervisory Board, Managing Director of SMAG Consulting, Supervisory Board member of Nanobiotix SA, Board member of Sartorius Stedim Biotech SA, Former Vice President at Sanofi Pasteur MSD.

Dr Kathrin U Jansen, Ph.D. (DE)

Member of the Supervisory Board, Former Senior Vice President and Head of Vaccine Research and Development (VRD) at Pfizer Inc. and member of Pfizer’s Worldwide Research, Development and Medical leadership team. Previously served as Senior Vice President at Wyeth Pharmaceuticals after 12 years at Merck Research Laboratories. Member of the National Academy of Medicine, National Academy of Engineering, a Fellow of the Royal Society of Medicine and recipient of the Albert B Sabin Gold Medal.

Sharon Tetlow (U.S.)

Member of the Supervisory Board, Founder and Managing Partner of Potrero Hill Advisors, Member of the Board of Directors and Audit Committee Chair of Catalyst Biosciences (NASDAQ:CBIO).

Johanna Willemina Pattenier (CH)

Member of the Supervisory Board, Former General Manager of Novartis Vaccines and Diagnostics in Basel (now a GlaxoSmithKline company) and GSK / Novartis vaccines integration lead. Previously held various commercial and medical roles at GSK, Organon and Byk Gulden.

Maïlys Ferrère for Bpifrance (FR)

Member of the Supervisory Board, Director of Large Venture Investments at Bpifrance, Former Investment Director at the Fonds Stratégique d’Investissement.

James Edward Connolly (US)

Member of the Supervisory Board, More than three decades of experience in the life sciences industry. Former Executive Vice President and General Manager, Wyeth Vaccines and President, Wyeth Canada

Scientific Advisory Board

Valneva announced the formation of a Scientific Advisory Board (SAB) as part of the evolution of its governance structure in July 2019.

Dr. Ralf Clemens, MD, Ph.D. Chair

Member of Board of Trustees International Vaccine Institute IVI, member GHIT scientific selection committee, Advisor Bill & Melinda Gates Foundation, former Head/Senior Vice President Vaccine Development at GSK, Novartis and Takeda

Dr. Norman W. Baylor, Ph.D.

President and CEO of Biologics Consulting, Temporary Advisor to the World Health Organization; Former Director of the US FDA Office of Vaccines Research and Review; Former FDA Liaison to the Centers for Disease Control’s Advisory Committee on Immunization Practices

Dr. Thomas Decker

Professor of Immunobiology at the Max Perutz Labs of the University of Vienna; President of the European Macrophage and Dendritic Cell Society (EMDS), Member of editorial boards for the scientific journals Molecular Cell Biology and Journal of Biochemistry.

Alexander von Gabain

Co-founder of Intercell and member of Valneva’s SAB. He is also holding an observer seat on Valneva’s Supervisory Board. Furthermore, he is serving in the SAB of the Paul Ehrlich Institute, Frankfurt and in the Board of Trustees of the Institute of Science and Technology, Austria. He is Vice-President off duty at the Karolinska Intitutet, Stockholm.

Dr. Michael Pfleiderer, Ph.D.

Renowned expert in regulatory affairs and development of vaccines; Since 1998, Dr. Pfleiderer had been the Head of the Human Viral Vaccines Section at the Paul-Ehrlich-Institut (PEI), German Federal Institute for Vaccines and Biomedicines.

Dr. George R. Siber, MD, PhD

Adjunct Professor of Medicine at Johns Hopkins University, Co-founder and Board Member of Affinivax, Board Member of Genocea, former Supervisory Board Member of Crucell and former Executive Vice President and CSO of Wyeth Vaccines